攀登抗癌的珠峰:如何攻克“最难对付”的癌基因——RAS(综述)
  • RAS是众多实体瘤中高频突变的癌基因,在癌症的发生发展中发挥着重要作用;
  • 过去的几十年,学术界和产业界针对RAS基因功能异常,付出了很多的努力;然而,至今RAS基因突变,依然“无药可及”;
  • 干扰RAS蛋白在细胞膜上的定位、靶向RAS信号通路的下游蛋白、通过协同致死原理寻找靠谱的化合物、靶向RAS相关的代谢异常、设计全新的直接靶向突变的RAS蛋白,是目前研究的几个主流的方向;
  • 本文系统综述了RAS的特点和攻克RAS突变的可能方案。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Science [IF:41.845]

Drugging RAS: Know the enemy

癌基因RAS——了解你的劲敌

10.1126/science.aam7622

2017-03-17, Review

Abstract & Authors:展开

Abstract:收起
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.

First Authors:
Bjoern Papke

Correspondence Authors:
Channing J Der

All Authors:
Bjoern Papke,Channing J Der

评论